- Promore Pharma Interim report January – June 2022
- Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Second Quarter 2022
- Promore Pharma granted EU patent regarding treatment of chronic wounds
- The last clinic visit conducted in Promore Pharma’s phase II study of ensereptide
- Report from the Annual General Meeting of Promore Pharma AB held on 17 May 2022
Promore Pharma AB (publ) published its interim report for the second quarter 2022 on 30 August 2022.
The same day the company hosted a webcast telephone conference at 13.00 CET, with President and CEO Jonas Ekblom and CFO Erik Magnusson, where an update for the quarter and upcoming activities.